Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Isocitrate Dehydrogenase (IDH)
Cat. No. Product name CAS No.
DC8051 AG-120 (Ivosidenib) Featured

AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein.

DC8374 AG-221(Enasidenib) Featured

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.

DC10439 Vorasidenib (AG881) Featured

AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2).

DC5050 AGI-5198 Featured

AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

DC7174 AGI-6780 Featured

AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q (IC50=23 nM).

DC11719 BAY-1436032

BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.

DC10538 IDH-305 Featured

IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.

DC10830 IDH-889 Featured

IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM.

DC7982 Mutant IDH1-IN-1 Featured

Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).

DC12281 Olutasidenib (FT-2102) Featured

Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia.

DC28343 Mutant IDH1-IN-4

Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.

DC28576 DS-1001b Featured

DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.

DC44726 Enasidenib Mesylate Featured

Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).

DC45831 WT IDH1 Inhibitor 2

WT IDH1 Inhibitor 2 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM. WT IDH1 Inhibitor 2 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity.

DC46300 IDH-C227

IDH-C227 is a potent and selective IDH1R132H inhibitor. IDH-C227 has anticancer effcts.

DC48219 Safusidenib

Safusidenib is a novel IDH1 inhibitor for the treatment of IDH1-mutated tumors.

DC49742 AGI-12026

AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma.

DC70642 NCATS-SM5637

NCATS-SM5637 (NSC 791985) is a potent, selective mutant IDH1 inhibitor with IC50 of 81/72 nM for IDH1 mutant R132H/R132C, respctively.NCATS-SM5637 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations in engineered mIDH1-U87-xenograft mouse model, compared with the approved drug AG-120 (ivosidenib).

DC72374 (S,S)-GSK321

(S,S)-GSK321 is a (S,S)-enantiomer of GSK321.

Page 1 / Total 1 FirstPrevNextLastGoto